These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20378673)

  • 21. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint.
    Burkhardt O; Rauch K; Kaever V; Hadem J; Kielstein JT; Welte T
    Int J Antimicrob Agents; 2009 Jul; 34(1):101-2. PubMed ID: 19278835
    [No Abstract]   [Full Text] [Related]  

  • 22. In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii.
    Capone A; D'Arezzo S; Visca P; Petrosillo N;
    J Antimicrob Chemother; 2008 Aug; 62(2):422-3. PubMed ID: 18424790
    [No Abstract]   [Full Text] [Related]  

  • 23. Single daily high-dose tigecycline therapy of a multidrug-resistant (MDR) Klebsiella pneumoniae and Enterobacter aerogenes nosocomial urinary tract infection.
    Cunha BA; McDermott B; Nausheen S
    J Chemother; 2007 Dec; 19(6):753-4. PubMed ID: 18230562
    [No Abstract]   [Full Text] [Related]  

  • 24. Comment: tigecycline for the treatment of Acinetobacter infections: a case series.
    Curcio D
    Ann Pharmacother; 2008 Nov; 42(11):1717-8; author reply 1718. PubMed ID: 18827173
    [No Abstract]   [Full Text] [Related]  

  • 25. Minocycline--an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii.
    Bishburg E; Bishburg K
    Int J Antimicrob Agents; 2009 Nov; 34(5):395-401. PubMed ID: 19665876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tigecycline: a new glycylcycline for treatment of serious infections.
    Noskin GA
    Clin Infect Dis; 2005 Sep; 41 Suppl 5():S303-14. PubMed ID: 16080069
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates.
    Seifert H; Stefanik D; Wisplinghoff H
    J Antimicrob Chemother; 2006 Nov; 58(5):1099-100. PubMed ID: 16980293
    [No Abstract]   [Full Text] [Related]  

  • 28. [Bacterial resistance and a new antibiotic: tigecycline].
    Gobernado M
    Rev Esp Quimioter; 2006 Sep; 19(3):209-19. PubMed ID: 17099789
    [No Abstract]   [Full Text] [Related]  

  • 29. [ESBL--increasing resistance problems. Cephalosporins no longer obvious choice in diffuse infections].
    Hallgren H; Gustafsson I; Ripa T
    Lakartidningen; 2007 Dec; 104(51-52):3883-5. PubMed ID: 18232531
    [No Abstract]   [Full Text] [Related]  

  • 30. Use of tigecycline in pediatric clinical practice.
    Mastrolia MV; Galli L; De Martino M; Chiappini E
    Expert Rev Anti Infect Ther; 2017 Jun; 15(6):605-612. PubMed ID: 28395551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry.
    Curcio D; Fernández F; Cané A; Barcelona L; Stamboulian D
    Braz J Infect Dis; 2008 Jun; 12(3):198-201. PubMed ID: 18833403
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tigecycline, the first of a new class of antibiotics: the glycylcyclines].
    Bosó-Ribelles V; Roma-Sánchez E; Salavert-Lletí M; Hernández-Martí V; Poveda-Andrés JL
    Rev Esp Quimioter; 2007 Mar; 20(1):19-35. PubMed ID: 17530033
    [No Abstract]   [Full Text] [Related]  

  • 33. In vitro activity of tigecycline against clinical isolates of multidrug-resistant Acinetobacter baumannii in Siriraj Hospital, Thailand.
    Tiengrim S; Tribuddharat C; Thamlikitkul V
    J Med Assoc Thai; 2006 Nov; 89 Suppl 5():S102-5. PubMed ID: 17718251
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tigecycline: a review of a new glycylcycline antibiotic.
    Scheinfeld N
    J Dermatolog Treat; 2005; 16(4):207-12. PubMed ID: 16249141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chemotherapy of bacterial infectious diseases of the kidneys and urinary tract].
    Chernomordik AB
    Klin Med (Mosk); 1973 Oct; 51(10):50-4. PubMed ID: 4787279
    [No Abstract]   [Full Text] [Related]  

  • 37. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii.
    Navon-Venezia S; Leavitt A; Carmeli Y
    J Antimicrob Chemother; 2007 Apr; 59(4):772-4. PubMed ID: 17353223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tigecycline: place in therapy and important considerations.
    Garrelts JC; Schroeder T
    Am J Health Syst Pharm; 2006 Jul; 63(13):1233. PubMed ID: 16790574
    [No Abstract]   [Full Text] [Related]  

  • 39. Multidrug-resistant Acinetobacter baumannii pneumonia in lung transplant recipients.
    Sopirala MM; Pope-Harman A; Nunley DR; Moffatt-Bruce S; Ross P; Martin SI
    J Heart Lung Transplant; 2008 Jul; 27(7):804-7. PubMed ID: 18582814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similarities and differences between doxycycline and minocycline: clinical and antimicrobial stewardship considerations.
    Cunha BA; Baron J; Cunha CB
    Eur J Clin Microbiol Infect Dis; 2018 Jan; 37(1):15-20. PubMed ID: 28819873
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.